公开(公告)号：US20160038596A1

公开(公告)日：2016-02-11

申请号：US14773642

申请日：2014-03-11

申请人： DURECT CORPORATION ,  ZOGENIX, INC.

发明人： Jeremy C. WRIGHT ,  Wilma TAMRAZ ,  John J. LEONARD ,  John W. GIBSON ,  Keith E. BRANHAM ,  Stefania SJOBECK ,  Brooks Boyd ,  Christopher M. RUBINO

IPC分类号： A61K47/22 ,  A61K47/26 ,  A61M5/20 ,  A61M5/24 ,  A61M5/30 ,  A61M5/315 ,  A61K31/519 ,  A61K47/20

CPC分类号： A61K47/22 ,  A61K9/0019 ,  A61K9/0021 ,  A61K31/519 ,  A61K47/20 ,  A61K47/26 ,  A61M5/2033 ,  A61M5/2046 ,  A61M5/2053 ,  A61M5/24 ,  A61M5/30 ,  A61M5/315 ,  A61M2205/8206

摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

摘要翻译： 组合物可以包括药物活性剂，高粘度液体载体材料（HVLCM），乳酸基聚合物和有机溶剂。 还公开了相关的组合物和方法。 例如，公开了用于可注射药物的控制释放的载体制剂。 制剂可以包括非水溶性高粘度液体，其可以是异丁酸蔗糖酯，可以是聚（乳酸）（乙醇酸）的乳酸基聚合物和将组成保持在单相中的有机溶剂 在一个气氛中在25℃下形成。 制剂中的药物可以在给药时释放，使得在最初的5小时内少于10％（例如2-8％）的药物被释放; 10％至80％的药物在给药后5小时至7天内释放; 10％〜40％的药物在初次给药后7天内逐渐释放至28天。 药物可以是通过注射递送的抗精神分裂症药物。

公开(公告)号：US20220280646A1

公开(公告)日：2022-09-08

申请号：US17671447

申请日：2022-02-14

申请人： DURECT CORPORATION

发明人： Jeremy C. WRIGHT ,  Wilma TAMRAZ ,  John J. LEONARD ,  John W. GIBSON ,  Keith E. BRANHAM ,  Stefania SJOBECK ,  Brooks Boyd ,  Christopher M. RUBINO

IPC分类号： A61K47/22 ,  A61K9/00 ,  A61K31/519 ,  A61K47/20 ,  A61K47/26 ,  A61M5/20 ,  A61M5/24 ,  A61M5/30 ,  A61M5/315

摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

公开(公告)号：US20210015924A1

公开(公告)日：2021-01-21

申请号：US16889115

申请日：2020-06-01

申请人： DURECT CORPORATION

发明人： Jeremy C. WRIGHT ,  Wilma TAMRAZ ,  John J. LEONARD ,  John W. GIBSON ,  Keith E. BRANHAM ,  Stefania SJOBECK ,  Brooks Boyd ,  Christopher M. RUBINO

IPC分类号： A61K47/22 ,  A61K9/00 ,  A61K31/519 ,  A61K47/20 ,  A61K47/26 ,  A61M5/20 ,  A61M5/24 ,  A61M5/30 ,  A61M5/315

摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic- acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

公开(公告)号：US20180036412A1

公开(公告)日：2018-02-08

申请号：US15652655

申请日：2017-07-18

申请人： DURECT CORPORATION

发明人： Jeremy C. WRIGHT ,  Wilma TAMRAZ ,  John J. LEONARD ,  John W. GIBSON ,  Keith E. BRANHAM ,  Stefania SJOBECK ,  Brooks Boyd ,  Christopher M. RUBINO

IPC分类号： A61K47/22 ,  A61K9/00 ,  A61K31/519 ,  A61M5/315 ,  A61K47/20 ,  A61M5/24 ,  A61K47/26 ,  A61M5/20 ,  A61M5/30

CPC分类号： A61K47/22 ,  A61K9/0019 ,  A61K9/0021 ,  A61K31/519 ,  A61K47/20 ,  A61K47/26 ,  A61M5/2033 ,  A61M5/2046 ,  A61M5/2053 ,  A61M5/24 ,  A61M5/30 ,  A61M5/315 ,  A61M2205/8206

摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

公开(公告)号：US09572812B2

公开(公告)日：2017-02-21

申请号：US14995658

申请日：2016-01-14

申请人： DURECT CORPORATION ,  ZOGENIX INC.

发明人： Jeremy C. Wright ,  Wilma Tamraz ,  John J. Leonard ,  John W. Gibson ,  Keith E. Branham ,  Stefania Sjobeck ,  Brooks Boyd ,  Christopher M. Rubino

IPC分类号： A61K9/19 ,  A61M5/30 ,  A61K31/519 ,  A61K9/00 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  A61K9/10 ,  A61K9/16 ,  A61K47/10 ,  A61K47/14 ,  A61K47/20 ,  A61K47/44 ,  A61K9/14 ,  A61M5/20 ,  A61M5/31

CPC分类号： A61K31/519 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/10 ,  A61K9/14 ,  A61K9/1623 ,  A61K9/1647 ,  A61K9/19 ,  A61K41/0019 ,  A61K47/10 ,  A61K47/14 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/34 ,  A61K47/44 ,  A61M5/30 ,  A61M2005/2013 ,  A61M2005/2073 ,  A61M2005/312 ,  C08G63/08 ,  C08G63/912

摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.

摘要翻译： 组合物可以包括药物活性剂，高粘度液体载体材料（HVLCM），乳酸基聚合物和有机溶剂。 还公开了相关的组合物和方法。

公开(公告)号：US10226532B2

公开(公告)日：2019-03-12

申请号：US15652655

申请日：2017-07-18

申请人： DURECT CORPORATION

发明人： Jeremy C. Wright ,  Wilma Tamraz ,  John J. Leonard ,  John W. Gibson ,  Keith E. Branham ,  Stefania Sjobeck ,  Brooks Boyd ,  Christopher M. Rubino

IPC分类号： A61K9/00 ,  A61M5/20 ,  A61M5/24 ,  A61M5/30 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61M5/315 ,  A61K31/519

摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

公开(公告)号：US11285217B2

公开(公告)日：2022-03-29

申请号：US16889115

申请日：2020-06-01

申请人： DURECT CORPORATION

发明人： Jeremy C. Wright ,  Wilma Tamraz ,  John J. Leonard ,  John W. Gibson ,  Keith E. Branham ,  Stefania Sjobeck ,  Brooks Boyd ,  Christopher M. Rubino

IPC分类号： A61K47/22 ,  A61K9/00 ,  A61K31/519 ,  A61K47/20 ,  A61K47/26 ,  A61M5/20 ,  A61M5/24 ,  A61M5/30 ,  A61M5/315

摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

公开(公告)号：US20190255179A1

公开(公告)日：2019-08-22

申请号：US16250614

申请日：2019-01-17

申请人： DURECT CORPORATION

发明人： Jeremy C. WRIGHT ,  Wilma TAMRAZ ,  John J. LEONARD ,  John W. GIBSON ,  Keith E. BRANHAM ,  Stefania SJOBECK ,  Brooks Boyd ,  Christopher M. RUBINO

IPC分类号： A61K47/22 ,  A61M5/20 ,  A61K47/20 ,  A61K47/26 ,  A61K9/00 ,  A61M5/24 ,  A61M5/30 ,  A61M5/315 ,  A61K31/519

摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

公开(公告)号：US09737605B2

公开(公告)日：2017-08-22

申请号：US14773642

申请日：2014-03-11

申请人： DURECT CORPORATION ,  ZOGENIX, INC.

发明人： Jeremy C. Wright ,  Wilma Tamraz ,  John J. Leonard ,  John W. Gibson ,  Keith E. Branham ,  Stefania Sjobeck ,  Brooks Boyd ,  Christopher M. Rubino

IPC分类号： A61K47/22 ,  A61K9/00 ,  A61K31/519 ,  A61K47/20 ,  A61K47/26 ,  A61M5/20 ,  A61M5/24 ,  A61M5/30 ,  A61M5/315

CPC分类号： A61K47/22 ,  A61K9/0019 ,  A61K9/0021 ,  A61K31/519 ,  A61K47/20 ,  A61K47/26 ,  A61M5/2033 ,  A61M5/2046 ,  A61M5/2053 ,  A61M5/24 ,  A61M5/30 ,  A61M5/315 ,  A61M2205/8206

摘要： Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.